Colorectal cancer molecular biology moves into clinical practice
Top Cited Papers
Open Access
- 4 October 2010
- Vol. 60 (1) , 116-129
- https://doi.org/10.1136/gut.2009.206250
Abstract
The promise of personalised medicine is now a clinical reality, with colorectal cancer genetics at the forefront of this next major advance in clinical medicine. This is no more evident than in the recent advances in testing of colorectal cancers for specific molecular alterations in order to guide treatment with the monoclonal antibody therapies cetuximab and panitumumab, which target the epidermal growth factor receptor. In this review, genetic mechanisms of colorectal cancer and how these alterations relate to emerging biomarkers for early detection and risk stratification (diagnostic markers), prognosis (prognostic markers) and the prediction of treatment responses (predictive markers) are examined.Keywords
This publication has 112 references indexed in Scilit:
- Sensitive digital quantification of DNA methylation in clinical samplesNature Biotechnology, 2009
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancerBritish Journal of Cancer, 2009
- Genomic and Epigenetic Instability in Colorectal Cancer PathogenesisGastroenterology, 2008
- PI3K pathway alterations in cancer: variations on a themeOncogene, 2008
- Functional classification analysis of somatically mutated genes in human breast and colorectal cancersGenomics, 2008
- Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapyBritish Journal of Cancer, 2007
- CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancerNature Genetics, 2006
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- RAF/RAS oncogenes and mismatch-repair statusNature, 2002
- The Hallmarks of CancerCell, 2000